Organon & Co. (NYSE:OGN) Receives Average Rating of “Hold” from Analysts

Shares of Organon & Co. (NYSE:OGN) have been assigned an average recommendation of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $20.80.

A number of analysts have recently issued reports on the company. Barclays cut their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Morgan Stanley lowered their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. Finally, TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th.

Organon & Co. Stock Performance

OGN opened at $15.34 on Tuesday. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The stock has a market cap of $3.96 billion, a price-to-earnings ratio of 4.61, a PEG ratio of 0.90 and a beta of 0.76. The business has a 50 day moving average of $15.46 and a 200-day moving average of $16.68. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. On average, equities research analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were paid a dividend of $0.28 per share. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.30%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Hedge Funds Weigh In On Organon & Co.

A number of hedge funds have recently added to or reduced their stakes in OGN. CWA Asset Management Group LLC acquired a new stake in shares of Organon & Co. in the 3rd quarter valued at $355,000. Crossmark Global Holdings Inc. boosted its holdings in shares of Organon & Co. by 43.4% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 20,157 shares of the company’s stock valued at $385,000 after purchasing an additional 6,096 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Organon & Co. by 47.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 259,831 shares of the company’s stock valued at $4,971,000 after purchasing an additional 83,510 shares in the last quarter. Versor Investments LP boosted its holdings in shares of Organon & Co. by 47.0% in the 3rd quarter. Versor Investments LP now owns 47,026 shares of the company’s stock valued at $900,000 after purchasing an additional 15,026 shares in the last quarter. Finally, Verus Capital Partners LLC boosted its holdings in shares of Organon & Co. by 65.4% in the 3rd quarter. Verus Capital Partners LLC now owns 39,193 shares of the company’s stock valued at $750,000 after purchasing an additional 15,501 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.